Abstract
Aims: Diabetic nephropathy progresses at a variable rate part of which may be explained by genetic polymorphisms. ApoE polymorphisms are associated with progression of atherosclerosis and because of the similarities between atherosclerosis and glomerulosclerosis, we chose to examine apoE and its role in progression of diabetic nephropathy. Methods: The apoE genotypes of 90 patients with type 2 diabetes and nephropathy who were recruited into a 2-year prospective randomised controlled study comparing intensive medical management with routine clinical care were analysed. The primary endpoint was the rate of progression of renal disease in the second year. Results: The apoE genotype frequencies were 49 with E3/3, 20 with E2/3, 17 with E3/4 and 4 with of E2/4. There were no significant differences in age, degree of renal failure, BP, albuminuria or glycaemic control between any genotype. The rate of progression of renal failure of patients with the E3/4 genotype was 0.80 ml/min/month compared to 0.30 ml/min/month for E2/3 and 0.18 ml/min/month for those with E3/3. Patients with E3/4 genotype had significantly faster rates of progression in the second year when compared with the other 3 genotypes (0.80 vs. 0.25 ml/min/month, p = 0.012). There was no difference in mortality according to apoE genotype. Conclusion: Patients who possess the apoE3/4 genotype had significantly faster rates of progression of renal failure.
Journal Section:
Original Paper
References
1.
Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH: Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int 1989;35:681–687.
[PubMed]
2.
Fava S, Azzopardi J, Hattersley AT, Watkins PJ: Increased prevalence of proteinuria in diabetic sibs of proteinuric type 2 diabetic subjects. Am J Kidney Dis 2000;35:708–712.
[PubMed]
3.
Diamond JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991;31:S29–S34.
4.
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133–140.
[PubMed]
5.
Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laakso M, Kesaniemi YA: Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 1993;101:9–15.
[PubMed]
6.
Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1–21.
[PubMed]
7.
Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137–147.
[PubMed]
8.
Joss N, Ferguson C, Brown C, Deighan CJ, Paterson KR, Boulton-Jones JM: Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004;97:219–227.
[PubMed]
9.
Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
[PubMed]
10.
Gaffney D, Reid JM, Cameron IM, Vass K, Caslake MJ, Shepherd J, Packard CJ: Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:1025–1029.
[PubMed]
11.
Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
[PubMed]
12.
Curtiss LK, Boisvert WA: Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000;11:243–251.
[PubMed]
13.
Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–1031.
[PubMed]
14.
Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA: Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004;15:2125–2138.
[PubMed]
15.
Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M: Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998;31:666–673.
[PubMed]
16.
Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K: Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002;40:243–251.
[PubMed]
17.
Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F, Hansen BV, Parving HH: Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 2000;15:625–630.
[PubMed]
18.
Boizel R, Benhamou PY, Corticelli P, Valenti K, Bosson JL, Halimi S, Boize R: ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 1998;13:72–75.
[PubMed]
19.
Kalina A, Szalai C, Prohaszka Z, Reiber I, Csaszar A: Association of plasma lipid levels with apolipoprotein E polymorphism in type 2 diabetes. Diabetes Res Clin Pract 2002;56:63–68.
[PubMed]
20.
Schachter F, Faure-Delanef L, Guenot F: Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29–32.
[PubMed]
21.
Araki S, Koya D, Makiishi T, Sugimoto T, Isono M, Kikkawa R, Kashiwagi A, Haneda M: APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 2003;26:2416–2420.
[PubMed]
22.
Soedamah-Muthu SS, Colhoun HM, Taskinen MR, Idzior-Walus B, Fuller JH: Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. Diabetologia 2000;43:1353–1359.
[PubMed]
23.
Lehtinen S, Rantalaiho V, Wirta O: Apolipoprotein E gene polymorphism, hypercholesterolaemia and glomerular filtration rate in type 2 diabetic subjects: A 9 year follow up study. J Biol Chem 2003;10:260–265.
24.
Roussos L, Floren CH, Carlson J, Svensson PJ, Wallmark A, Ekberg H: Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients. Nephron 1999;83:25–30.
[PubMed]
25.
Kasiske BL, O’Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880–891.
[PubMed]
26.
Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia – a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994;45:S125–S131.
27.
Rayner BL, Byrne MJ, van Zyl SR: A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 1996;46:219–224.
[PubMed]
28.
Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000;67:427–431.
[PubMed]
29.
Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980–987.
[PubMed]
30.
Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260–269.
[PubMed]
31.
Mahley RW, Huang Y: Apolipoprotein E: from atherosclerosis to Alzheimer’s disease and beyond. Curr Opin Lipidol 1999;10:207–217.
[PubMed]
32.
Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ: A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989;83:1015–1031.
[PubMed]
33.
Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M: Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. Clin Nephrol 1991;36:127–133.
[PubMed]
34.
Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S: A protective role for kidney apolipoprotein E: regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 2001;276:49142–49147.
[PubMed]
35.
Bruneval P, Bariety J, Belair MF, Mandet C, Heudes D, Nicoletti A: Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 2002;17:2099–2107.
[PubMed]
36.
Gracia V, Fiol C, Hurtado I, Pinto X, Argimon JM, Castineiras MJ: An enzyme-linked immunosorbent assay method to measure human apolipoprotein E levels using commercially available reagents: effect of apolipoprotein E polymorphism on serum apolipoprotein E concentration. Anal Biochem 1994;223:212–217.
[PubMed]
© 2005 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2005
You do not currently have access to this content.
